CVM Cel-Sci

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. Its product pipeline includes Multikine and Ligand Epitope Presentation System (LEAPS). Multikine is an investigational immunotherapy for the potential treatment of head and neck cancers. LEAPS is categorized into LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza for hospitalized patients; and CEL-2000 and CEL-4000 which are vaccine candidates for the treatment of rheumatoid arthritis. The company was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Company profile

Geert R. Kersten
Fiscal year end
Former names
IRS number

CVM stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


12 Feb 21
18 Apr 21
30 Sep 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Sep 20 Sep 19 Sep 18 Sep 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Cel-Sci earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 21.86M 21.86M 21.86M 21.86M 21.86M 21.86M
Cash burn (monthly) (positive/no burn) (positive/no burn) 2.91M 2.57M 1.28M 1.25M
Cash used (since last report) n/a n/a 10.53M 9.31M 4.62M 4.52M
Cash remaining n/a n/a 11.33M 12.55M 17.24M 17.34M
Runway (months of cash) n/a n/a 3.9 4.9 13.5 13.9

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
31 Mar 21 Kersten Geert R Common Stock Grant Aquire A No No 15.21 285 4.33K 1,120,797
31 Mar 21 Prichep Patricia B Common Stock Grant Aquire A No No 15.21 269 4.09K 206,738
31 Mar 21 Talor Eyal Common Stock Grant Aquire A No No 15.21 157 2.39K 119,405
31 Mar 21 Zimmerman Daniel H Common Stock Grant Aquire A No No 15.21 248 3.77K 115,743
31 Dec 20 Kersten Geert R Common Stock Grant Aquire A No No 11.66 366 4.27K 1,120,512

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

30.5% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 116 114 +1.8%
Opened positions 18 18
Closed positions 16 9 +77.8%
Increased positions 36 30 +20.0%
Reduced positions 26 29 -10.3%
13F shares
Current Prev Q Change
Total value 410.35M 994.76M -58.7%
Total shares 12.37M 11.93M +3.6%
Total puts 5.52M 5.56M -0.7%
Total calls 1.73M 2.18M -20.4%
Total put/call ratio 3.2 2.6 +24.7%
Largest owners
Shares Value Change
BLK Blackrock 2.47M $28.83M +5.5%
STT State Street 1.98M $23.07M +10.5%
Vanguard 1.75M $20.41M +4.0%
D. E. Shaw & Co. 889.52K $10.37M +1.2%
Susquehanna International 656.56K $7.66M -6.6%
Geode Capital Management 507.46K $5.92M +5.2%
NTRS Northern Trust 390.63K $4.56M -2.0%
ATAC Neuberger Berman 337.46K $3.94M 0.0%
D.a. Davidson & Co. 310.94K $3.63M +2.6%
Sabby Management 310.16K $3.62M +187.5%
Largest transactions
Shares Bought/sold Change
Sabby Management 310.16K +202.28K +187.5%
STT State Street 1.98M +187.8K +10.5%
BLK Blackrock 2.47M +128.42K +5.5%
SG Americas Securities 74.27K -120.7K -61.9%
Vanguard 1.75M +67.9K +4.0%
Natixis 66.2K +66.2K NEW
Susquehanna International 656.56K -46.57K -6.6%
Tower Research Capital 2.31K -44.41K -95.1%
BAC Bank Of America 58.31K -44.1K -43.1%
GS Goldman Sachs 92.3K -39.98K -30.2%
Content analysis
H.S. sophomore Bad
New words: analyzed, analyzing, awaiting, CC, CDC, chemotherapy, clarify, clarity, committed, composition, concept, Conversion, convey, Disease, environment, fight, HH, immune, knowledge, landlord, LL, local, minimize, month, monthly, multiple, properly, protocol, prove, radiation, range, readout, ready, repaid, repayment, rheumatoid, ROU, scientific, simplify, Simplifying, strong, Subtopic, surgery, training, treat, TT, understated, upgrade, variation
Removed: account, accurate, acquiring, applied, assessing, charged, codified, compare, contract, cumulative, DD, depreciation, determining, discovered, EDGAR, EE, error, Europharma, fluctuation, identification, Innovation, Interactive, lab, large, leasing, long, modified, necessarily, omission, optional, Orient, package, patented, permitting, point, policy, portfolio, practical, proof, recognition, recognize, record, reimbursed, removed, renewal, restate, resulting, retrospective, SBIR, Small, TEVA, transition, twelve, underwriter, unpatented, updated, vary, XBRL